Browse the latest research summaries in the field of pain management for spinal cord injury patients and caregivers.
Showing 21-30 of 682 results
Frontiers in Immunology, 2024 • December 6, 2024
This scoping review characterizes the changes in spinal microglia over time in murine models of chronic pain. This study also evaluates the importance of the time points that different studies used to...
KEY FINDING: Most studies used inbred, young adult, male mice with peripheral nerve injury, limiting the generalizability of the data.
Neurosurgical Review, 2025 • January 1, 2025
This study compares the surgical outcomes of DREZL between patients with SCI and those with CEI to investigate predictors of favorable operative outcomes. The CEI group demonstrated significant pain i...
KEY FINDING: Patients with CEI had significantly better long-term pain reduction after DREZotomy compared to those with SCI.
CNS Neuroscience & Therapeutics, 2025 • January 1, 2025
The study aimed to understand how NDSM, known for analgesic efficacy, works to relieve pain, focusing on GABAA receptors and neuroinflammation. The results indicate that NDSM's analgesic effects are p...
KEY FINDING: NDSM demonstrates significant analgesic effects against chronic pain in both pain-evoked and pain-suppressed behavioral assays.
eNeuro, 2025 • January 1, 2025
The study investigated TrkB signaling in DRG neurons as a potential neural mechanism that underlies pain hypersensitivity after SCI. The results revealed that TrkB-mediated inward current and its prot...
KEY FINDING: SCI decreased 7,8-DHF-induced current while increasing the latency to its peak amplitude.
Cell Biol Toxicol, 2025 • January 1, 2025
This study investigates the effect of Comp 6d, a novel SIRT1 activator, on neuropathic pain and explores its mechanisms. The findings suggest that Comp 6d alleviates neuropathic pain by specifically a...
KEY FINDING: Comp 6d alleviates neuropathic pain by specifically activating SIRT1 in the spinal cord, as demonstrated by the abolishment of its effects in SIRT1 knockout mice.
Communications Biology, 2025 • January 9, 2025
This study uses spatial transcriptomics (ST), single-nucleus RNA-sequencing (snRNA-seq) and bulk RNA-sequencing (bulk RNA-seq) to characterize regional pathological heterogeneity of the spinal cord (S...
KEY FINDING: The study found unique spatial atlases of genes, cell populations, cell-cell cross-talks, signaling pathways, and transcriptional regulatory networks in the spinal cord of neuropathic pain mice compared to sham mice.
Frontiers in Neuroanatomy, 2025 • January 7, 2025
This review discusses the limitations of current neuropathic pain treatments and introduces a novel approach using capsaicin and RTX. Preclinical data suggests that applying these substances to uninju...
KEY FINDING: In an animal model of neuropathic pain, application of capsaicin or RTX to adjacent uninjured nerves completely alleviated and prevented mechanical and thermal hyperalgesia following L5 nerve injury.
Scientific Reports, 2025 • January 14, 2025
This study investigates the therapeutic effect of NaHS on neuropathic pain using the spared nerve injury (SNI) model in mice, focusing on astrocytes and glutamate. The findings reveal that NaHS enhanc...
KEY FINDING: SNI induces chronic pain and depressive-like behaviors in mice, evidenced by decreased mechanical pain threshold, thermal pain latency, and reduced exploratory behavior.
J. Clin. Med., 2025 • January 20, 2025
The aim of this study was to evaluate the effects of spinal cord stimulation (SCS) on pain, neuropathic symptoms, and other health-related metrics in patients with chronic painful peripheral neuropath...
KEY FINDING: SCS produced a significant consistent and sustained improvement in pain intensity by 49% in DN4 and 76% in VAS.
Brain Behav Immun, 2025 • March 1, 2025
This study demonstrates that blocking or deleting the neonatal Fc receptor (FcRn) can alleviate neuropathic pain in mice after sciatic nerve injury. The researchers used efgartigimod, an FcRn blocker,...
KEY FINDING: Efgartigimod, an FcRn blocker, alleviated mechanical allodynia when administered either 7 or 28 days post-CCI.